Submit Written Comments

About

Submission windows are open prior to all Board and Stakeholder Council meetings to ensure your feedback is reviewed before any final actions are taken.

Current Opportunities for Public Comment

Written Comment Request: Posted 8/31/2026

In accordance with COMAR 14.01.01.05B(4), the Prescription Drug Affordability Board requests public written comment for the cost review study process on:

Dupixent (dupilumab)
Drug Brand Name: Dupixent
Active Moiety or Active Ingredient: dupilumab
Application Number: BLA761055
NDC 11s in the Cost Review Study Process - PDF - 86.75 KB

AND

Skyrizi (risankizumab)
Drug Brand Name: Skyrizi
Active Moiety or Active Ingredient: risankizumab
Application Number: BLA761105
NDC 11s in the Cost Review Study Process - PDF - 87.53 KB

Patient experience and clinician input regarding these drugs are of particular interest but all comments concerning these drug products are encouraged. Written comments are due by the close of business, Tuesday, September 15, 2026. Please submit written comments to [email protected] with the subject line “(Drug Name) Comments.”

Comments should be submitted to [email protected]